source
- Labcorp reports Q2 sales of $3.73 billion, lifts full-year revenue outlook despite missing consensusLabcorp announced second‑quarter revenue of $3.73 billion, up from $3.53 billion a year earlier, driven by strong performance across its core businesses. The Diagnostics division grew 5.5% to $2.9…
- Takeda drops its second celiac disease candidate, TAK-101, after unimpressive phase 2 resultsTakeda said it is halting development of TAK-101, its second candidate for celiac disease, after a phase 2 study failed to meet expectations. TAK-101 is a nanoparticle that carries gliadin, a glut…